Castration-resistant Prostate Cancer

• CLINICAL_TRIALS trial_result · 2025-05-29
  Clinical Trial Update: Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy [Phase 1, Phase 2]

  This update reports results from a Phase 1/2 study of NGM120 in combination therapy for patients with advanced solid tumors, including pancr…

• CLINICAL_TRIALS trial_result · 2025-05-20
  Clinical Trial Update: 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression [Phase 1]

  Phase 1 trial evaluating the PET imaging tracer 11C-YJH08 for detecting glucocorticoid receptor expression in prostate cancer; the study was…

• CLINICAL_TRIALS trial_result · 2025-05-15
  Clinical Trial Update: Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 [Phase 2]

  This is a Phase 2 trial evaluating 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. The study is currently re…

• CLINICAL_TRIALS trial_result · 2025-05-14
  Clinical Trial Update: 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1]

  Phase 1 clinical trial update evaluating the combination of Lutetium-177-PSMA-617 and olaparib in metastatic castration-resistant prostate c…

• CLINICAL_TRIALS trial_result · 2025-05-13
  Clinical Trial Update: ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer [Phase 1]

  Phase 1 trial evaluating ARRx in combination with enzalutamide for metastatic castration-resistant prostate cancer was terminated, with resu…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-05-13
  Clinical Trial Update: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer [Phase 1]

  Phase 1 trial of 177Lu-PSMA-R2 in PSMA-positive metastatic castration-resistant prostate cancer has been terminated.

• CLINICAL_TRIALS trial_result · 2025-05-08
  Clinical Trial Update: M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

  Phase 2 trial evaluating M6620 in combination with carboplatin, with or without docetaxel, for metastatic castration-resistant prostate canc…

• CLINICAL_TRIALS trial_result · 2025-04-29
  Clinical Trial Update: Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) [Phase 1]

  A Phase 1 (Phase IB) trial evaluating Radium-223 dichloride in combination with niraparib for castration-resistant, metastatic prostate canc…

• CLINICAL_TRIALS trial_result · 2025-04-24
  Clinical Trial Update: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy [Phase 2]

  A Phase 2 clinical trial evaluating sacituzumab govitecan in metastatic castration-resistant prostate cancer that progressed on second-gener…

• CLINICAL_TRIALS trial_result · 2025-04-17
  Clinical Trial Update: A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer [Phase 2]

  A Phase 2 trial comparing patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castration-resistant pro…

• CLINICAL_TRIALS trial_result · 2025-04-11
  Clinical Trial Update: Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC [Phase 1]

  Phase 1 clinical trial evaluating the safety and preliminary efficacy of Universal PSMA CAR-T cells in patients with refractory metastatic c…

• CLINICAL_TRIALS trial_result · 2025-04-08
  Clinical Trial Update: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

  A Phase 1/2 trial of PLX2853 in combination with Abiraterone acetate and prednisone, and in combination with Olaparib, for Metastatic Castra…

• CLINICAL_TRIALS trial_result · 2025-04-04
  Clinical Trial Update: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) [Phase 1]

  JEWEL-101 is a Phase 1 trial of XB002 in patients with solid tumors, covering multiple indications. The study has completed.

• CLINICAL_TRIALS trial_result · 2025-04-02
  Clinical Trial Update: TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors [Phase 1, Phase 2]

  Clinical trial update for TT-10 and TT-4 (Portage Biotech) exploring single-agent and combination therapy in advanced solid tumors, with rec…

• CLINICAL_TRIALS trial_result · 2025-04-01
  Clinical Trial Update: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

  A Phase 1 clinical evaluation of the radiopharmaceutical 177Lu-DansyI-PSMA (LNC1011) for metastatic castration-resistant prostate cancer has…

• CLINICAL_TRIALS trial_result · 2025-04-01
  Clinical Trial Update: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)

  A clinical trial evaluating whole-body MRI in metastatic castration-resistant prostate cancer patients treated with Lu-PSMA has been termina…

• CLINICAL_TRIALS trial_result · 2025-04-01
  Clinical Trial Update: Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 1, Phase 2]

  This clinical trial update reports that the Phase 1/2 study of ARV-110 in metastatic castration-resistant prostate cancer has been completed…

• CLINICAL_TRIALS trial_result · 2025-03-30
  Clinical Trial Update: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer [Phase 2]

  A Phase 2 trial in men with advanced prostate cancer compares the combination of cediranib and olaparib to olaparib alone, with results post…

• CLINICAL_TRIALS trial_result · 2025-03-21
  Clinical Trial Update: Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer [Phase 1]

  A Phase 1 clinical trial is evaluating 225Ac-PSMA-617 in men with PSMA-positive prostate cancer, including castration-resistant cases; the s…

• CLINICAL_TRIALS trial_result · 2025-03-19
  Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]

  A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety,…

• CLINICAL_TRIALS trial_result · 2025-03-04
  Clinical Trial Update: Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

  This completed trial compares changes in tumor burden using 68Ga-PSMA-11 PET/CT versus 177Lu-PSMA SPECT/CT in metastatic castration-resistan…

• CLINICAL_TRIALS trial_result · 2025-03-04
  Clinical Trial Update: PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing

  This clinical trial update reports the completion of a study assessing the usefulness of 18F-FDG PET/CT in patients with metastatic castrati…

• CLINICAL_TRIALS trial_result · 2025-02-28
  Clinical Trial Update: EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC [Phase 1, Phase 2]

  A Phase 1/2 trial evaluating EPI-7386 in combination with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate…

• CLINICAL_TRIALS trial_result · 2025-02-25
  Clinical Trial Update: 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

  This clinical trial update reports results from a Phase 1 study evaluating the combination of Lutetium-177-PSMA-617 and pembrolizumab in pat…

• CLINICAL_TRIALS trial_result · 2025-02-17
  Clinical Trial Update: P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) [Phase 1]

  Poseida Therapeutics conducted a Phase 1 trial of P-PSMA-101 CAR-T cells in metastatic castration-resistant prostate cancer and advanced sal…